Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu HengRui Medicine Co., Ltd.
With
Peking University Cancer Hospital & Institute
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Life expectancy of more than 12 weeks.
Histologically or cytologically confirmed high-grade papillary-serous epithelial ovarian cancer，primary peritoneal, or fallopian tube cancers; subjects with a known deleterious breast cancer gene (BRCA) mutation and any other high-grade histology are also eligible. Subjects should have platinum-sensitive disease, where platinum-sensitive disease is defined as having had a \> 6 month interval since last receiving platinum therapy prior to disease recurrence. Additionally, subjects with histologically or cytologically confirmed triple negative breast cancer (TNBC）, that is locally advanced or metastatic, are also eligible.
Prior therapy：subjects with ovarian cancer，primary peritoneal, or fallopian tube cancers have received only 2 lines of platinum-based chemotherapies, and TNBC patients have received only 1 line of standard chemotherapy. Each prior chemotherapy must be given for at least 2 cycles.
At least one measurable lesion that can be accurately assessed by imaging (CT/MRI) at baseline
Subjects who have overall good overall general condition.
Signed informed consent.
You may not be if
Subjects who received any previous treatment with any PARP inhibitors.
Subjects who received any previous treatment with any VEGFR inhibitors.
Less than 4 weeks from the last clinical trial.
Less than 4 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment and target therapy.
Unstable or uncontrolled hypertension.
Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption.
Subjects with brain metastases.
Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.
Subjects with a known hypersensitivity to fluzoparib, apatinib or any of the excipients of the products.
Ongoing infection (determined by investigator).
History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.
